Lapatinib (Synonyms: 拉帕替尼; GW572016; GW2016) 纯度: 99.83%
Lapatinib (GW572016) 是一种 ErbB-2 和 EGFR 酪氨酸激酶结构域的有效抑制剂,对纯化的 EGFR 和 ErbB-2 的 IC50 值分别为 10.2 和 9.8 nM。
Lapatinib Chemical Structure
CAS No. : 231277-92-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥770 | In-stock | |
50 mg | ¥700 | In-stock | |
100 mg | ¥1200 | In-stock | |
500 mg | ¥3000 | In-stock | |
1 g | ¥4500 | In-stock | |
5 g | 询价 | ||
10 g | 询价 |
* Please select Quantity before adding items.
Lapatinib 相关产品
•相关化合物库:
- Covalent Screening Library Plus
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- FDA-Approved Drug Library Mini
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Immunology/Inflammation Compound Library
- JAK/STAT Compound Library
- Kinase Inhibitor Library
- Protein Tyrosine Kinase Compound Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- CNS-Penetrant Compound Library
- Autophagy Compound Library
- Drug Repurposing Compound Library
- Covalent Screening Library
- Differentiation Inducing Compound Library
- Ferroptosis Compound Library
- Anti-COVID-19 Compound Library
- Orally Active Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Anti-Hepatitis C Virus Compound Library
- Anti-Breast Cancer Compound Library
- Anti-Lung Cancer Compound Library
- Drug-Induced Liver Injury (DILI) Compound Library
- Anti-Pancreatic Cancer Compound Library
- Targeted Therapy Drug Library
- Angiogenesis Related Compound Library
- Anti-Liver Cancer Compound Library
- Rare Diseases Drug Library
- Anti-Colorectal Cancer Compound Library
生物活性 |
Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1]. |
||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
|
||||||||||||||||||||||||
体外研究 (In Vitro) |
Lapatinib (GW2016; 0.03-10 µM; 6 hours; BT474 and HN5 cells) treatment inhibits receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner. Phosphorylation of serine 473 of AKT was inhibited by GW2016 in a dose-dependent manner[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[1]
Cell Proliferation Assay[1]
Cell Cycle Analysis[1]
|
||||||||||||||||||||||||
体内研究 (In Vivo) |
Lapatinib (GW2016; 30-100 mg/kg; oral administration; twice daily; for 21 days; CD-1 nude female mice) treatment inhibits tumor xenograft growth of the HN5 cells in a dose-responsive manner at 30 and 100 mg/kg, with complete inhibition of tumor growth at the higher dose[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||||||||||
Clinical Trial |
|
||||||||||||||||||||||||
分子量 |
581.06 |
||||||||||||||||||||||||
Formula |
C29H26ClFN4O4S |
||||||||||||||||||||||||
CAS 号 |
231277-92-2 |
||||||||||||||||||||||||
中文名称 |
拉帕替尼 |
||||||||||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||||||
储存方式 |
|
||||||||||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 125 mg/mL (215.12 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||||||||||
参考文献 |
|